Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Sho Watanabe

3PUBLICATIONS

23CO-AUTHORS

Tumour immunologyMolecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (3)

Sort by Publication Date:

|Nov 27, 2024

The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.

Ayaka Tsuge, Sho Watanabe, Akihito Kawazoe

|Oct 07, 2022

BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors.

Kota Itahashi, Takuma Irie, Junichiro Yuda

|Jan 20, 2021

HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.

Sho Watanabe, Yasushi Goto, Hiroyuki Yasuda

Pageof 1

Frequent Collaborators

2 joint publications

Kota Itahashi

2 joint publications

Shohei Koyama

2 joint publications

Hiroyoshi Nishikawa

1 joint publications

Junichiro Yuda

1 joint publications

Tokiyoshi Tanegashima

1 joint publications

Yi-Tzu Lin

1 joint publications

Masahiro Tsuboi

1 joint publications

Genichiro Ishii

1 joint publications

Yuichiro Ohe

1 joint publications

Tomohiro Kurosaki

Frequent Collaborators

2 joint publications

Kota Itahashi

2 joint publications

Shohei Koyama

2 joint publications

Hiroyoshi Nishikawa

1 joint publications

Junichiro Yuda

Top Related Videos

<em>Ex Vivo</em> Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

<em>Ex Vivo</em> Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on : Oct 02, 2014

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on : Jan 20, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos

Top Related Videos

<em>Ex Vivo</em> Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

<em>Ex Vivo</em> Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on : Oct 02, 2014

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on : Jan 20, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

See more related videos